These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14611929)

  • 1. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
    Garyfallos G; Dimelis D; Kouniakis P; Sidiropoulos N; Karastergiou A; Lavrentiadis G; Giouzepas J; Fokas K
    Eur Psychiatry; 2003 Oct; 18(6):320-1. PubMed ID: 14611929
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
    Robinson DG; Woerner MG; Napolitano B; Patel RC; Sevy SM; Gunduz-Bruce H; Soto-Perello JM; Mendelowitz A; Khadivi A; Miller R; McCormack J; Lorell BS; Lesser ML; Schooler NR; Kane JM
    Am J Psychiatry; 2006 Dec; 163(12):2096-102. PubMed ID: 17151160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
    Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
    Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
    Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
    Shim JC; Choe BM; Kim JG; Jae YM; Kim HC; Kim SG; Oh MK; Kelly DL; Conley RR
    J Clin Psychopharmacol; 2007 Aug; 27(4):400-1. PubMed ID: 17632229
    [No Abstract]   [Full Text] [Related]  

  • 12. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?
    Suzuki T; Takeuchi H; Watanabe K
    J Clin Psychiatry; 2010 Nov; 71(11):1553-4; author reply 1554. PubMed ID: 21114953
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Authors' response to comments regarding risperidone versus olanzapine Markov model.
    Value Health; 2005; 8(5):613-4. PubMed ID: 16176499
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
    Misiak B; Frydecka D; Łaczmański Ł; Ślęzak R; Kiejna A
    Eur J Clin Pharmacol; 2014 Dec; 70(12):1433-41. PubMed ID: 25291992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine increases weight and serum triglyceride levels.
    Osser DN; Najarian DM; Dufresne RL
    J Clin Psychiatry; 1999 Nov; 60(11):767-70. PubMed ID: 10584766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.